Effect of Early Administration of TXA in Adult Hip Fractures

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

NCT Number	NCT05047133
Lead Sponsor	Ascension Health
Conditions	Postoperative Blood Loss
Enrollment	170 participants
Start Date	2021-09-01
Primary Completion	2022-07-01 (estimated)
Study Completion	2022-07-01 (estimated)
Updated on ClinicalTrials.gov	2021-09-16